Allergy Therapeutics Plc reported strong growth in European sales for the year to 30 June, giving it a platform for the future launch of its candidate short-course vaccine against grass allergy, Pollinex Quattro Grass. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
